Trial Profile
Phase II trial of talactoferrin alfa in combination with paclitaxel and carboplatin as first-line therapy in patients with non-small cell lung cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 31 May 2011
Price :
$35
*
At a glance
- Drugs Talactoferrin alfa (Primary) ; Carboplatin; Paclitaxel
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 26 May 2011 Results published in the Journal of Thoracic Oncology, according to an Agennix media release.
- 05 Nov 2010 New trial record.